Publications

Categories
Zanidatamab
June 4, 2023
ASCO
Zanidatamab, a HER2-targeted Bispecific Antibody, in Combination With Docetaxel as First-line Therapy for Patients With Advanced HER2-positive Breast Cancer: Updated Results From a Phase 1b/2 Study
Wang et al.
Preclinical
June 2, 2023
Bioorganic & Medicinal Chemistry Letters
Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates
Brant et al.
Zanidatamab
June 2, 2023
Lancet Oncology
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Harding et al.
Zanidatamab
June 2, 2023
ASCO
Results from the Pivotal Phase 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-treated HER2-amplified Biliary Tract Cancer (BTC)
Pant et al.
ZW171
May 19, 2023
PEGS
Engineering and Preclinical Development of ZW171: A 2+1 Format Anti-MSLN T Cell Engager
Piscitelli et al.
Preclinical
May 15, 2023 - May 19, 2023
PEGS
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Bhojane et al.
Preclinical
May 15, 2023 - May 19, 2023
PEGS
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
Preclinical
May 10, 2023
STING & TLR-Targeting Therapies Summit
Evaluation of TLR7-agonists as payloads for immune-stimulating antibody conjugates
Graham Garnett
Zanidatamab
April 18, 2023
AACR
ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a Phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
Shpektor et al.
Preclinical
April 18, 2023
AACR
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Newhook et al.
Preclinical
April 17, 2023
AACR
Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer
Barnscher et al.
Preclinical
April 17, 2023
AACR
ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Hernández et al.